Updated Date: Wed, 29 Apr 2020 00:00:00 EDT

Updated Date: Wed, 29 Apr 2020 00:00:00 EDT

Updated Date: Wed, 29 Apr 2020 00:00:00 EDT

Updated Date: Wed, 29 Apr 2020 00:00:00 EDT

Updated Date: Wed, 29 Apr 2020 00:00:00 EDT

The approval gives NSCLC patients whose tumours carry the MET exon 14 skipping mutation a new treatment option

RBX2660 may bring an innovative therapeutic option to patients suffering from C. diff

Amgen is planning to file for FDA approval of Otezla in mild to moderate plaque psoriasis based on […]

The news on cardiopulmonary resuscitation (CPR) in covid-191 is the latest example of the state of confusion, denial, […]

Guidelines that advise doctors to manage common infant symptoms as cow’s milk allergy are not evidence based and […]